DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07030621

STARS

Not yet recruitingPhase 3

Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial

Lead sponsor

RenJi Hospital

Asset

Semaglutide

GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

436

estimated

Study population

Stroke

Key I/E criterion

—

Primary endpoint

•MRS at 90-days

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07030621
Org study ID2025-175

Timeline

Milestones

Study first posted2025-06-22actual
Last update posted2025-06-22actual
Study start2025-07-01estimated
Primary completion2027-07-31estimated
Study completion2028-01-31estimated

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Stroke

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

1. Clinical or imaging diagnosis of acute ischemic stroke within 24 hours after onset;

2. Scheduled for endovascular thrombectomy;

3. Age ≥18 years;

4. Pre-stroke modified Rankin Scale (mRS) score ≤1;

5. Informed consent voluntarily signed by the patient or legal representative.

Exclusion criteria

1. Preoperative imaging diagnosis of intracranial hemorrhage, or history of intracranial hemorrhage within 3 months prior to surgery;

2. Contraindications for endovascular thrombectomy;

3. Recent history of ischemic stroke;

4. Fasting blood glucose <3.9 mmol/L;

5. ASA classification of IV-V;

6. Severe organic heart disease or severe arrhythmia;

7. Pregnant or lactating women;

8. Contraindications to semaglutide or allergy to semaglutide.

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
2
Cardiovascular outcomes
1
Safety / tolerability / PK
1

Cardiovascular outcomes

1 endpoint
Secondary/protocol endpoint

Infarct volume after 72 hours of treatment

Time frame:72 hours postoperatively

descriptive, improvement

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

the incidence of surgical complications within 90 days postoperatively

Time frame:within 90 days postoperatively

time to event, event

Other clinical outcomes

2 endpoints
Primary/protocol endpoint

mRS at 90-days

Time frame:90 days postoperatively

categorical status, improvement

Secondary/protocol endpoint

National Institute of Health Stroke Scale (NIHSS) at 24 hours and 7-days

Time frame:A decrease of ≥8 points in the NIHSS score from baseline to 24 hours and 7 days postoperatively, or a score of 0 to 1, indicates neurological improvement; an increase of ≥4 points indicates neurological deterioration.

change from baseline, improvement

Publications (12)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.